1. Severe Type <br/ >Respiratory distress, RR >30 times/min <br/ >Finger oxygen saturation <93% in rest state <br/ >Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation FiO2 >300mmHg <br/ >2. Critical type: meeting any of the following criteria <br/ >Respiratory failure occurs and mechanical ventilation is required <br/ >Patients go into shock <br/ >ICU is needed for other organ failure. <br/ >3.Patients who have received tumor immunotherapy such as <br/ >PD-1/L1 CTLA4 etc. in the past 1 month, and inflammatory factor modulators such as Ulinastatin. <br/ >4.other viral pneumonia <br/ >5.patients who have received tumor immunotherapy in the past one <br/ >month and inflammatory factor modulators such as Ulinastatin <br/ >6. patients who have received organ transplantation or surgery <br/ >planning in the past 6 months <br/ >7. patients who cant take food or drugs due to coma or intestinal obstruction <br/ >8.Patients who have severe underlying diseases that affects survival,including uncontrolled malignant tumor with multiple metastases that <br/ >cannot be resected, blood diseases, dyscrasia, active bleeding,severe malnutrition, etc <br/ >9.Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period <br/ >10.Allergic to systemic enzyme supplements <br/ >11.Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper <br/ >limit of normal, or patients with child-Pugh grade C cirrhosis <br/ >12.ECLS (ECMO, ECCO2R, RRT) <br/ >13.Imminent death in the opinion of the clinical team <br/ >14.Patients who have participated in any other clinical study within 2 weeks prior to randomization <br/ >15.The investigator concludes that the patient is not suitable for the study

1. Severe Type <br/ >Respiratory distress, RR >30 times/min <br/ >Finger oxygen saturation <93% in rest state <br/ >Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation FiO2 >300mmHg <br/ >2. Critical type: meeting any of the following criteria <br/ >Respiratory failure occurs and mechanical ventilation is required <br/ >Patients go into shock <br/ >ICU is needed for other organ failure. <br/ >3.Patients who have received tumor immunotherapy such as <br/ >PD-1/L1 CTLA4 etc. in the past 1 month, and inflammatory factor modulators such as Ulinastatin. <br/ >4.other viral pneumonia <br/ >5.patients who have received tumor immunotherapy in the past one <br/ >month and inflammatory factor modulators such as Ulinastatin <br/ >6. patients who have received organ transplantation or surgery <br/ >planning in the past 6 months <br/ >7. patients who cant take food or drugs due to coma or intestinal obstruction <br/ >8.Patients who have severe underlying diseases that affects survival,including uncontrolled malignant tumor with multiple metastases that <br/ >cannot be resected, blood diseases, dyscrasia, active bleeding,severe malnutrition, etc <br/ >9.Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period <br/ >10.Allergic to systemic enzyme supplements <br/ >11.Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper <br/ >limit of normal, or patients with child-Pugh grade C cirrhosis <br/ >12.ECLS (ECMO, ECCO2R, RRT) <br/ >13.Imminent death in the opinion of the clinical team <br/ >14.Patients who have participated in any other clinical study within 2 weeks prior to randomization <br/ >15.The investigator concludes that the patient is not suitable for the study

N/A

N/A

1. Severe Type <br/ >Respiratory distress, RR >30 times/min <br/ >Finger oxygen saturation <93% in rest state <br/ >Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation FiO2 >300mmHg <br/ >2. Critical type: meeting any of the following criteria <br/ >Respiratory failure occurs and mechanical ventilation is required <br/ >Patients go into shock <br/ >ICU is needed for other organ failure. <br/ >3.Patients who have received tumor immunotherapy such as <br/ >PD-1/L1 CTLA4 etc. in the past 1 month, and inflammatory factor modulators such as Ulinastatin. <br/ >4.other viral pneumonia <br/ >5.patients who have received tumor immunotherapy in the past one <br/ >month and inflammatory factor modulators such as Ulinastatin <br/ >6. patients who have received organ transplantation or surgery <br/ >planning in the past 6 months <br/ >7. patients who cant take food or drugs due to coma or intestinal obstruction <br/ >8.Patients who have severe underlying diseases that affects survival,including uncontrolled malignant tumor with multiple metastases that <br/ >cannot be resected, blood diseases, dyscrasia, active bleeding,severe malnutrition, etc <br/ >9.Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period <br/ >10.Allergic to systemic enzyme supplements <br/ >11.Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper <br/ >limit of normal, or patients with child-Pugh grade C cirrhosis <br/ >12.ECLS (ECMO, ECCO2R, RRT) <br/ >13.Imminent death in the opinion of the clinical team <br/ >14.Patients who have participated in any other clinical study within 2 weeks prior to randomization <br/ >15.The investigator concludes that the patient is not suitable for the study

1. Severe Type <br/ >Respiratory distress, RR >30 times/min <br/ >Finger oxygen saturation <93% in rest state <br/ >Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation FiO2 >300mmHg <br/ >2. Critical type: meeting any of the following criteria <br/ >Respiratory failure occurs and mechanical ventilation is required <br/ >Patients go into shock <br/ >ICU is needed for other organ failure. <br/ >3.Patients who have received tumor immunotherapy such as <br/ >PD-1/L1 CTLA4 etc. in the past 1 month, and inflammatory factor modulators such as Ulinastatin. <br/ >4.other viral pneumonia <br/ >5.patients who have received tumor immunotherapy in the past one <br/ >month and inflammatory factor modulators such as Ulinastatin <br/ >6. patients who have received organ transplantation or surgery <br/ >planning in the past 6 months <br/ >7. patients who cant take food or drugs due to coma or intestinal obstruction <br/ >8.Patients who have severe underlying diseases that affects survival,including uncontrolled malignant tumor with multiple metastases that <br/ >cannot be resected, blood diseases, dyscrasia, active bleeding,severe malnutrition, etc <br/ >9.Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period <br/ >10.Allergic to systemic enzyme supplements <br/ >11.Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper <br/ >limit of normal, or patients with child-Pugh grade C cirrhosis <br/ >12.ECLS (ECMO, ECCO2R, RRT) <br/ >13.Imminent death in the opinion of the clinical team <br/ >14.Patients who have participated in any other clinical study within 2 weeks prior to randomization <br/ >15.The investigator concludes that the patient is not suitable for the study